HeartBeam inc (BEAT)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.43+1.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · BEAT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
License 3D ECG signal technology to partners and tailor technology for multiple markets to expand global reach.
Newly stated in 2026-06-24. Management announced a strategic shift to license its 3D ECG platform globally through partners and adapt technology for various markets. No revenue data is available to measure progress, so the trajectory is currently unquantified.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Expand platform beyond arrhythmia assessment into reliable heart attack detection to address a large unmet need in cardiac care.
Newly stated in 2026-06-24. Management is focused on developing heart attack detection capabilities beyond arrhythmia, but this indication is not yet FDA cleared and no financial or operational metrics are available, so progress is qualitative and unmeasured.
Reorganize operations around focused teams to improve accountability, sharpen focus, and reduce costs.
Newly stated in 2026-06-24. Management announced a leaner, focused structure to reduce costs. Operating income improved slightly from -$5.5M in 2025-Q1 to -$5.1M in 2026-Q2, indicating limited progress toward cost reduction but some positive trajectory.
Use proceeds from public offering to advance commercialization of FDA-cleared 12-lead synthesized ECG system and related initiatives.
Newly stated in 2026-04-16. Management plans to use proceeds from a public offering to advance commercialization of the FDA-cleared 12-lead ECG system. No revenue or commercialization metrics are available to assess progress, so trajectory is unquantified.
Navigate CEO and CFO departures and ensure leadership continuity with new executive appointments and retention agreements.
Newly stated in 2026-08-14. Management is managing leadership transitions with CEO and CFO departures and retention agreements for new executives. No financial impact metrics are available, so progress is qualitative.
Over the trailing year it converted 0.77x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.